The majority of HIV-1-infected individuals develop neutralizing antibodies (NAbs) against the gp120 and gp41 subunits of the envelope glycoprotein (Env), which drive the rapid selection of antibody escape variants 1,2 . Env uses multiple mechanisms to escape from antibody neutralization, including amino acid substitutions, insertions in the variable domains of gp120 [2] [3] [4] and increasing the number of glycan moieties on its outer surface 2, 5, 6 .
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Recently, evidence has been provided that HIV-1 adapts over time to host cellular immune responses by losing epitopes restricted by the most abundant human leukocyte antigen types in a population 7 . Here we tested the hypothesis that, over the course of the epidemic, HIV-1 has also become more resistant to antibody neutralization.
We compared the neutralization sensitivity of clonal subtype B HIV-1 variants that we isolated within 4.5 months after seroconversion from individuals who seroconverted either between 1985 and 1989 (historical seroconverters) or between 2003 and 2006 (contemporary seroconverters) (Supplementary Table 1 and Supplementary Methods). Sensitivity to neutralization by two HIVIg preparations, which are pools of purified IgG obtained in 1995 from chronically HIV-1-infected individuals 8 , tended to be higher for viruses from historical seroconverters than from contemporary seroconverters (HIVIg batch 1, P = 0.020, Fig. 1a ; HIVIg batch 2, P = 0.089, Fig. 1b ).
As this difference in neutralization sensitivity may result from the fact that the antibodies in these preparations were more specific for historical viruses because they were elicited in response to virus variants that were circulating more than 15 years ago, we also determined the sensitivity of historical and contemporary viruses to neutralization by antibodies that were elicited by contemporary viruses. Individual sera from 22 unrelated contemporary HIV-infected individuals had a higher mean neutralizing antibody titer against viruses from historical seroconverters than from contemporary seroconverters (P = 0.050; Fig. 1c) , which was particularly evident for serum from subject M31281 (P = 0.0001; Fig. 1d ). These observations excluded the possibility that the lower neutralization sensitivity of contemporary HIV-1 variants was related to the calendar time from which the HIVIg preparations or the sera originated.
HIV-1 variants from historical seroconverters were also more sensitive to neutralization by the CD4 binding site-directed monoclonal antibody (mAb) b12 (P = 0.005; Fig. 1e ) but not the glycan-binding mAb 2G12 or the gp41-directed mAb 2F5 (Fig. 1f,g ). In contrast, we observed a trend toward increased sensitivity of contemporary viruses to neutralization by gp41-directed mAb 4E10 (P = 0.070; Fig. 1h) . Altogether, these data suggest that HIV-1 may have evolved toward a more neutralization-resistant phenotype and, in particular, toward resistance to CD4 binding site-directed neutralizing activity.
The mechanism underlying the increased resistance to antibody neutralization could potentially influence immunogenicity and the development of NAb responses in newly infected individuals. To study this, we analyzed sera that we obtained approximately 3 years after seroconversion from individuals who seroconverted in 1985-1986 (n = 31), 1987-1989 (n = 25) or 1990-1996 (n = 25) for their neutralization breadth against a multiple-subtype panel of 23 virus variants 9 (Supplementary Methods). This revealed a decreasing ability over the course of the epidemic to neutralize heterologous virus variants (P = 0.004; Fig. 1i ). Moreover, sera from individuals who seroconverted in 1990-1996 showed less neutralization potency against subtype B and C viruses (P = 0.040 and P = 0.029, respectively; Supplementary  Fig. 1a ) and a trend toward a decrease in neutralizing titers compared to sera from the earliest seroconverters (P = 0.054; Supplementary  Fig. 1b ). These findings suggest that individuals who became HIV-1-infected more recently developed poorer NAb responses than did individuals who seroconverted early in the epidemic.
Next, we studied the molecular basis for this increased neutralization resistance and decreased immunogenicity. The median total length of the variable regions of gp120 sequences increased from 144.5 amino acid residues in HIV-1 variants from historical seroconverters to 151.5 amino acid residues in HIV-1 variants from Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level By comparing HIV-1 variants from people who became infected at the beginning of the epidemic and from people who have recently contracted the virus, we observed an enhanced resistance of the virus to antibody neutralization over time, accompanied by an increase in the length of the variable loops and in the number of potential N-linked glycosylation sites on the HIV-1 envelope gp120 subunit. The enhanced neutralization resistance of HIV-1 in contemporary seroconverters coincided with the poorer elicitation of neutralizing antibody responses, which may have implications for vaccine design.
contemporary seroconverters (P = 0.003; Fig. 2a ). This change was largely the result of an increased length of the V1 region (P = 0.009; Fig. 2b ) and less so of the V4 region (P = 0.099; Fig. 2c) , whereas the length of V2, V3 and V5 regions remained the same over time (data not shown). Viruses from contemporary seroconverters contained a median of 1.5 additional potential N-linked glycosylation sites (PNGSs) in gp120 as compared to viruses from historical seroconverters (P = 0.003; Fig. 2d ), and these PNGSs were located mainly in the variable regions (P = 0.046; Fig. 2e ) and, again, particularly in the V1 loop (P = 0.007; Fig. 2f) .
We obtained HIV-1 variants from historical and contemporary seroconverters at, on average, 2.3 and 1.1 months after seroconversion, respectively (P = 0.002, Student's t test). However, virus populations from both subject groups were equally homogeneous with regard to their genetic diversity (average diversity of 0.28% and 0.36% for historical and contemporary gp120 sequences, respectively, P > 0.1, Student's t test) and had not diversified with respect to length or number of PNGSs, in agreement with the reported limited viral evolution in the first months after infection 10, 11 . Moreover, envelope characteristics within each group were not associated with the time point of virus isolation after seroconversion (data not shown). Therefore, differences in sampling time point are unlikely to account for the differences in the envelope characteristics between historical and contemporary HIV-1 variants.
Phylogenetic analysis showed that the gp120 sequences of viruses from our study subjects did not cluster separately from subtype B gp120 sequences from the Los Alamos database ( Supplementary  Fig. 2 (Fig. 2g) . However, the median length of the V1V2 loop tended to increase from 65.0 to 67.5 amino acids in historical compared to contemporary sequences (P = 0.083; Fig. 2h) . Moreover, contemporary gp120 sequences contained a median of one additional PNGS compared to historical sequences (P = 0.031; Fig. 2i) , which again could be attributed mainly to the V1 region (P = 0.049; Fig. 2j) . These results suggest that the adaptation of HIV-1 is not restricted to our cohort. Notably, we also observed an increase in V1 length and number of PNGSs in V1 between historical and contemporary subtype C gp120 sequences obtained from the Los Alamos database (Supplementary Fig. 3 ). It will be worthwhile to confirm whether the adaptation of HIV-1 to humoral immunity has also occurred for other HIV-1 subtypes.
Given our results, we propose that, over a period of 20 years, subtype B HIV-1 has adapted to the humoral immune response by enhancing the masking of its envelope. We found the largest changes in the V1 loop, which is the prime target of the autologous NAb response 12, 13 and is thought to protect underlying vulnerable epitopes from antibody recognition 14 . As the increased neutralization resistance of contemporary HIV-1 seems to coincide with a blunted NAb response in contemporary seroconverters, these findings may be relevant for the choice of envelope in vaccine design. 
